6 results
Profiles of Antidiabetic Medications - AACE 2018 

#Antidiabetic #Medications #Profiles #SideEffects #Table #DecisionAid #Orals #DM2 #Diabetes
#Profiles #SideEffects ... #Table #DecisionAid ... #Orals #DM2 #Diabetes ... #Endocrinology ... #Pharmacology #Management
DPP-4 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits DPP-4 (dipeptidyl peptidase 4), which normally inactivates GLP-1
- Pharmacology ... failure Common Side Effects ... #Pharmacology # ... Summary #DM2 #diabetes ... #endocrinology
SGLT2 Inhibitors 
SGLT2 inhibitors are the newest class of anti-diabetic medications, with the first one (Canagliflozin)
class of anti-diabetic ... medications, with ... #Pharmacology # ... Medications #DM2 ... #Diabetes #Endocrinology
Diabetes Mellitus Type 2 Inpatient Medication Guide

Classes: Biguanide, Sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT2i,
Type 2 Inpatient Medication ... α-glucosidase inhibitor ... #pharmacology # ... comparison #table ... #endocrinology
DPP4 Inhibitors - Normal and Renal Dosing

Increase Incretins (GLP-I & GIP) -> Stimulates Insulin, Inhibits Glucagon
different than other medications ... very tolerable medication ... Renal #Dosing #Pharmacology ... #Management #Diabetes ... #DM2 #Endocrinology
Pituitary Mass Effects - Pathogenesis and Clinical Findings
 • Pituitary turnors are almost always a benign
targeted with medication ... Signs / Symptoms ... Hyperprolactinemia • Diabetes ... #Macroadenoma #SideEffects ... #endocrinology